<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329755</url>
  </required_header>
  <id_info>
    <org_study_id>16 CUTA 05</org_study_id>
    <nct_id>NCT03329755</nct_id>
  </id_info>
  <brief_title>Optimization of the Patient Care Pathway in Immuno-oncology</brief_title>
  <acronym>OPTIMMUNO</acronym>
  <official_title>Optimization of the Patient Care Pathway in Immuno-oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the care pathway of melanoma patients treated by immunotherapy in two&#xD;
      ambulatory care structures. The aim is to measure if a care structure specialized in&#xD;
      immuno-oncology could rationalize the care of patients.&#xD;
&#xD;
      This protocol will be based on two different follow-up during the treatment period:&#xD;
&#xD;
        -  dedicated and coordinated e-follow-up (IUCT-O in Toulouse)&#xD;
&#xD;
        -  standard follow-up (University Hospital Center in Bordeaux)&#xD;
&#xD;
      Patients will be followed from the first cycle of immunotherapy until 3 months after the&#xD;
      initiation treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 26, 2017</start_date>
  <completion_date type="Actual">February 19, 2021</completion_date>
  <primary_completion_date type="Actual">February 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average length of administrative stay in the hospital</measure>
    <time_frame>3 months by patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cancelled or delayed hospital stay</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life using the Quality of Life Questionnaire Core 30 (QLQ-C30)</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response rate at 3 months</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the day hospital stay and the patient general health</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of web interface completion (Experimental arm only)</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction to the e-follow-up (Experimental arm only)</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reclassified alerts after intervention of nurse (Experimental arm only)</measure>
    <time_frame>3 months by patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dedicated and coordinated e-follow-up during the treatment period</intervention_name>
    <description>Completion of questionnaires using an electronic tool&#xD;
Telephone follow-up between the nurse and the patient&#xD;
Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard follow-up during the treatment period</intervention_name>
    <description>- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with advanced (unresectable melanoma (stage III)) or metastatic (stage IV)&#xD;
             melanoma and starting an Immune Checkpoint Inhibitor treatment (Monotherapy or&#xD;
             Combination Therapy)&#xD;
&#xD;
          2. Patient starting first cycle of Immune Checkpoint Inhibitor treatment in an ambulatory&#xD;
             care structure&#xD;
&#xD;
          3. Treatment which can be delayed for 7 days or more&#xD;
&#xD;
          4. Age &gt; or = 18 years old&#xD;
&#xD;
          5. Patient with a phone and/or computer equipment&#xD;
&#xD;
          6. Patient affiliated to the french social security system&#xD;
&#xD;
          7. Patient must provide written informed consent prior to any study-specific procedure or&#xD;
             assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with diagnosis other than advanced melanoma&#xD;
&#xD;
          2. Patient who must receive a treatment other than Immune Checkpoint Inhibitor&#xD;
&#xD;
          3. Treatment administered during a conventional hospital stay (period of more than 24&#xD;
             hours)&#xD;
&#xD;
          4. Patient with no caregiver&#xD;
&#xD;
          5. Pregnant or breastfeeding women&#xD;
&#xD;
          6. Any psychological, familial, geographic or social situation, according to the judgment&#xD;
             of investigator, potentially preventing the provision of informed consent or&#xD;
             compliance to study procedure&#xD;
&#xD;
          7. Patient protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Saint André, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut claudius regaud IUCT ONCOPOLE</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced melanoma</keyword>
  <keyword>Immune checkpoint</keyword>
  <keyword>E-follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

